Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PediCRaFT: FMT in pediatric Crohn's disease
NCT03378167Phase 1Completed
- Sponsor
- McMaster Children's Hospital
- Start
- Dec 2018
- Primary completion
- Sep 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RBX2660 and RBX7455 in Crohn's disease, sponsored by McMaster Children's Hospital. Primary endpoints: Monthly Recruitment Rate at 30 weeks and Dropout Rate Post Enrolment at 30 weeks. Started Dec 2018; status: completed.
02
Drugs
RBX2660RBX7455
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03378167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378167.